Vir Biotechnology Inc. Misses Q4 EPS by 41c

  • Investing.com
Vir Biotechnology Inc. Misses Q4 EPS by 41c

Vir Biotechnology Inc . (NASDAQ: VIR ) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus estimate of $149.6 million.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles